

ONLINE SUPPLEMENT

eTable A. Economic and Health Indicators of Countries Examined

	Drug utilization data source ^a	Region ^b	Income (2020) ^b	GDP per capita (2020) ^b	Health expenditure per capita (2018) ^b	% of health expenditure ^b		Statins included in EML (2017) ^c	IHD mortality rate (2019) ^d
						Public	OOP		
Australia	Total market	East Asia & Pacific	High	\$51,812	\$5,425	69	18	-	56.1
Japan	Total market	East Asia & Pacific	High	\$40,113	\$4,267	84	13	-	29.9
New Zealand	Total market	East Asia & Pacific	High	\$41,792	\$4,037	75	13	-	75.0
Singapore	Total market	East Asia & Pacific	High	\$59,798	\$2,824	50	31	-	52.3
South Korea	Total market	East Asia & Pacific	High	\$31,489	\$2,543	58	33	-	35.0
Taiwan	Total market	East Asia & Pacific	High ^e	\$28,371 ^e	\$1,882 ^e	-	-	-	41.2
China	Total market	East Asia & Pacific	Upper middle	\$10,500	\$501	56	36	Yes	116.4
Indonesia	Total market	East Asia & Pacific	Upper middle	\$3,870	\$112	49	35	Yes	140.3
Malaysia	Total market	East Asia & Pacific	Upper middle	\$10,402	\$427	51	35	Yes	145.7
Thailand	Total market	East Asia & Pacific	Upper middle	\$7,189	\$276	76	11	Yes	52.6
Philippines	Total market	East Asia & Pacific	Lower middle	\$3,299	\$137	33	54	Yes	148.1
Vietnam	Total market	East Asia & Pacific	Lower middle	\$2,786	\$152	46	45	Yes	95.6
Austria	Total market	Europe	High	\$48,105	\$5,326	73	18	-	83.3
Belgium	Total market	Europe	High	\$44,594	\$4,913	76	19	-	54.8
Croatia	Total market	Europe	High	\$13,828	\$1,014	83	10	Yes	143.8
Czech Republic	Total market	Europe	High	\$22,762	\$1,766	83	14	Yes	149.0
Denmark	Total market	Europe	High	\$60,909	\$6,217	84	14	-	55.6
Estonia	Retail only	Europe	High	\$23,312	\$1,553	74	25	Yes	144.2
Finland	Total market	Europe	High	\$49,041	\$4,516	79	18	-	100.6
France	Total market	Europe	High	\$38,625	\$4,690	73	9	-	38.4
Germany	Total market	Europe	High	\$45,724	\$5,472	78	13	-	81.4
Greece	Retail only	Europe	High	\$17,676	\$1,567	52	36	-	91.9
Hungary	Total market	Europe	High	\$15,899	\$1,082	69	27	-	174.6
Ireland	Total market	Europe	High	\$83,813	\$5,489	74	12	-	74.7
Italy	Total market	Europe	High	\$31,676	\$2,989	74	24	-	55.3
Latvia	Total market	Europe	High	\$17,620	\$1,101	60	39	Yes	200.4
Lithuania	Total market	Europe	High	\$19,998	\$1,249	66	32	Yes	222.9
Luxembourg	Retail only	Europe	High	\$115,874	\$6,227	85	10	-	54.2
Netherlands	Total market	Europe	High	\$52,304	\$5,307	65	11	-	47.4
Norway	Total market	Europe	High	\$67,294	\$8,239	85	14	-	55.5
Poland	Total market	Europe	High	\$15,656	\$979	71	21	Yes	130.3
Portugal	Total market	Europe	High	\$22,440	\$2,215	61	30	Yes	45.8
Romania	Total market	Europe	High	\$12,896	\$687	80	19	Yes	177.1
Slovak Republic	Total market	Europe	High	\$19,157	\$1,300	79	19	Yes	198.9
Slovenia	Total market	Europe	High	\$25,180	\$2,170	72	12	Yes	59.0
Spain	Total market	Europe	High	\$27,057	\$2,736	70	22	-	45.0
Sweden	Total market	Europe	High	\$51,926	\$5,982	85	14	Yes	73.7
Switzerland	Total market	Europe	High	\$86,602	\$9,871	31	28	-	55.7
United Kingdom	Total market	Europe	High	\$40,285	\$4,315	79	17	-	66.8
Belarus	Total market	Europe	Upper middle	\$6,411	\$356	70	25	Yes	334.2
Bosnia & Herzegovina	Total market	Europe	Upper middle	\$6,032	\$540	70	29	Yes	162.9
Bulgaria	Total market	Europe	Upper middle	\$9,976	\$690	58	41	Yes	239.1
Russia	Total market	Europe	Upper middle	\$10,127	\$609	59	38	Yes	240.6
Serbia	Total market	Europe	Upper middle	\$7,666	\$617	59	38	Yes	204.4
Ukraine	Total market	Europe	Lower middle	\$3,727	\$228	48	49	Yes	424.2
Chile	Retail only	Latin America	High	\$13,232	\$1,456	51	33	Yes	50.4
Uruguay	Retail only	Latin America	High	\$15,438	\$1,590	73	17	Yes	67.0
Argentina	Retail only	Latin America	Upper middle	\$8,442	\$1,128	61	28	Yes	82.1
Brazil	Total market	Latin America	Upper middle	\$6,797	\$848	42	28	Yes	74.9
Colombia	Retail only	Latin America	Upper middle	\$5,333	\$513	72	15	Yes	75.3
Dominican Republic	Total market	Latin America	Upper middle	\$7,268	\$462	44	45	Yes	175.6
Ecuador	Retail only	Latin America	Upper middle	\$5,600	\$516	52	40	Yes	81.8
Mexico	Retail only	Latin America	Upper middle	\$8,347	\$520	50	42	Yes	100.0
Peru	Retail only	Latin America	Upper middle	\$6,127	\$369	63	29	Yes	48.7
Venezuela	Retail only	Latin America	Lower middle ^f	\$1,739 ^f	\$257	48	38	Yes	130.0
Central America ^g	Retail only								
Panama		Latin America	High	\$12,269	\$1,132	64	29	Yes	58.2
Costa Rica		Latin America	Upper middle	\$12,077	\$910	72	22	Yes	71.5
Guatemala		Latin America	Upper middle	\$4,603	\$260	36	58	Yes	106.3
El Salvador		Latin America	Lower middle	\$3,799	\$289	64	29	Yes	100.4
Honduras		Latin America	Lower middle	\$2,406	\$176	40	51	Yes	154.8
Nicaragua		Latin America	Lower middle	\$1,905	\$174	60	33	Yes	148.3

eTable A (continued). Economic and Health Indicators of Countries Examined

	Drug utilization data source ^a	Region ^b	Income (2020) ^b	GDP per capita (2020) ^b	Health expenditure per capita (2018) ^b	% of health expenditure ^b		Statins included in EML (2017) ^c	IHD mortality rate (2019) ^d
						Public	OOP		
Kuwait	Retail only	MENA	High	\$32,373	\$1,711	88	11	-	108.5
Saudi Arabia	Total market	MENA	High	\$20,110	\$1,485	62	14	-	205.6
United Arab Emirates	Retail only	MENA	High	\$43,103	\$1,817	52	13	-	175.4
Algeria	Retail only	MENA	Lower middle	\$3,310	\$256	66	33	Yes	237.3
Egypt	Retail only	MENA	Lower middle	\$3,548	\$126	29	62	Yes	359.3
Morocco	Retail only	MENA	Lower middle	\$3,009	\$175	40	47	Yes	278.5
Tunisia	Total market	MENA	Lower middle	\$3,320	\$252	57	39	Yes	193.5
Jordan	Retail only	MENA	Upper middle	\$4,283	\$330	49	31	Yes	121.9
Kazakhstan	Total market	MENA	Upper middle	\$9,056	\$276	61	33	-	251.4
Lebanon	Retail only	MENA	Upper middle	\$4,891	\$686	50	33	Yes	241.2
Turkey	Total market	MENA	Upper middle	\$8,538	\$390	77	17	-	121.0
Canada	Total market	North America	High	\$43,242	\$4,995	73	15	No	63.9
United States	Total market	North America	High	\$63,544	\$10,624	50	11	-	91.0
Bangladesh	Retail only	South Asia	Lower middle	\$1,969	\$42	17	74	No	111.2
India	Total market	South Asia	Lower middle	\$1,901	\$73	27	63	Yes	150.5
Pakistan	Retail only	South Asia	Lower middle	\$1,194	\$43	36	56	Yes	189.3
Sri Lanka	Retail only	South Asia	Lower middle	\$3,682	\$157	41	51	Yes	109.0
South Africa	Total market	Sub-Saharan Africa	Upper middle	\$5,091	\$526	54	8	Yes	81.4
West Africa ^g	Retail only								
Gabon		Sub-Saharan Africa	Upper middle	\$7,006	\$218	59	23	-	117.4
Benin		Sub-Saharan Africa	Lower middle	\$1,291	\$31	20	45	-	113.1
Cameroon		Sub-Saharan Africa	Lower middle	\$1,499	\$54	6	76	-	115.5
Côte d'Ivoire		Sub-Saharan Africa	Lower middle	\$2,326	\$72	29	39	-	122.0
Senegal		Sub-Saharan Africa	Lower middle	\$1,488	\$59	24	56	-	117.6
Burkina Faso		Sub-Saharan Africa	Low	\$831	\$40	43	36	-	130.2
Chad		Sub-Saharan Africa	Low	\$614	\$29	17	62	-	120.1
Democratic Republic of the Congo		Sub-Saharan Africa	Low	\$557	\$19	15	42	-	114.7
Guinea		Sub-Saharan Africa	Low	\$1,194	\$38	16	61	-	123.7
Mali		Sub-Saharan Africa	Low	\$859	\$35	28	34	-	116.0
Niger		Sub-Saharan Africa	Low	\$565	\$30	33	49	-	118.1
Togo		Sub-Saharan Africa	Low	\$915	\$42	17	56	-	134.9

Notes: EML=essential medicines list, IHD=ischemic heart disease, MENA=Middle East and North Africa, OOP=out-of-pocket.

a Based on “sell-in” data or the volume purchased by retail (*e.g.*, pharmacies) or non-retail (*e.g.*, hospitals) sectors. As an exception, we used “sell-out” data, or the volume dispensed to patients, in the United Kingdom. We present data on the total market, or retail and non-retail drug sales, for 52 countries. In the 39 countries lacking non-retail sector data, utilization was estimated by interpolation, using the ratio of statin consumption in the retail and non-retail sectors for other countries in their region for which data was available. In 2020, 85% of statins were dispensed via retail sectors (based on countries with data for retail and non-retail sectors). **b** World Bank. **c** World Health Organization. **d** Global Burden Disease, age-standardized IHD mortality rate. **e** Republic of China (Taiwan), Statistical Bureau. **f** Australian Department of Foreign Affairs & Trade, Venezuela Fact Sheet. **g** IQVIA does not provide country specific utilization for this region.

eTable B. Statin Utilization in Pre- and Post-COVID-19, October 2019 to September 2020

Countries/Regions ^b	Statin utilization, No.		<i>p</i>	Growth, %
	(DDD per 1000 population ≥ 40 y) ^a			
	Pre-COVID-19 (10/19 to 03/20)	Post-COVID-19 (04/20 to 09/20)		
Denmark	331.7	326.1	0.73	-1.7
Canada	322.9	314.3	0.68	-2.7
United Kingdom	324.5	308.8	0.14	-4.8
Australia	327.5	265.2	0.26	-19.0
Norway	304.7	274.4	0.26	-9.9
United States	271.6	271.2	.98	-0.1
Ireland	280.3	257.8	0.38	-8.0
Sweden	265.0	255.5	0.61	-3.6
New Zealand	275.3	243.6	0.74	-11.5
Greece	250.5	253.7	0.33	1.3
Slovenia	250.8	256.1	0.55	2.1
Belgium	271.5	243.0	0.14	-10.5
Czech Republic	241.7	248.3	0.15	2.7
Finland	253.0	243.2	0.47	-3.9
Netherlands	248.8	237.9	0.22	-4.4
Lebanon	201.9	232.4	0.17	15.1
Poland	241.2	202.5	0.32	-16.0
Austria	223.5	190.8	0.18	-14.7
Portugal	205.4	184.8	0.43	-10.0
Spain	188.6	180.1	0.51	-4.5
Luxembourg	198.1	176.2	0.21	-11.0
Latvia	193.1	174.8	0.40	-9.5
Hungary	192.9	175.0	0.30	-9.3
Switzerland	202.8	170.1	0.15	-16.1
Germany	180.6	160.6	0.27	-11.1
Slovak Republic	175.5	155.2	0.09	-11.6
Croatia	156.5	158.3	0.67	1.2
Estonia	174.5	148.9	0.39	-14.7
France	145.8	141.8	0.17	-2.7
Italy	144.7	135.1	0.52	-6.6
Romania	141.6	125.4	0.34	-11.4
Argentina	108.7	130.2	0.03	19.8
Uruguay	116.1	118.1	0.35	1.8
Algeria	108.9	111.6	0.88	2.5
Lithuania	113.8	106.0	0.52	-6.8
Brazil	107.0	112.0	0.25	4.7
Thailand	102.6	92.9	0.34	-9.4
Singapore	96.6	93.4	0.59	-3.3
Bulgaria	94.0	90.8	0.50	-3.4
South Korea	90.5	91.4	0.72	1.0
Taiwan	87.0	86.8	0.96	-0.2
South Africa	83.9	87.8	0.64	4.6
United Arab Emirates	92.7	77.8	0.60	-16.1
Serbia	85.1	78.7	0.25	-7.5
Saudi Arabia	72.1	81.1	0.26	12.4
Turkey	65.0	73.1	0.04	12.4
Bosnia	70.5	61.2	0.37	-13.2
Russia	58.6	66.2	0.08	13.0
Tunisia	76.5	52.7	0.05	-31.1
Malaysia	65.9	53.7	0.21	-18.6
Belarus	55.0	51.0	0.25	-7.2
Japan	53.2	54.1	0.82	1.7
Egypt	51.4	53.3	0.50	3.7
Chile	45.5	50.6	0.25	11.4
Sri Lanka	44.5	50.0	0.14	12.4
Dominican Republic	44.7	44.7	0.00	0.0
Kuwait	26.3	27.7	0.84	5.4
Ukraine	32.1	26.1	0.22	-18.7
Jordan	28.7	24.1	0.50	-16.1
Kazakhstan	22.8	22.9	0.97	0.8
Bangladesh	20.9	24.9	0.17	19.3

eTable B (continued). Statin Utilization in Pre- and Post-COVID-19, October 2019 to September 2020

Countries/Regions ^b	Statin utilization, No. (DDD per 1000 population ≥ 40 y) ^a			p	Growth, %
	Pre-COVID-19 (10/19 to 03/20)	Post-COVID-19 (04/20 to 09/20)			
	Mexico	28.4	23.8		
Philippines	23.2	21.3	0.54	-8.1	
Ecuador	18.1	22.3	0.30	23.6	
Pakistan	20.4	19.4	0.40	-4.8	
China	16.2	18.3	0.17	13.3	
Vietnam	23.3	17.2	0.38	-26.3	
Central America ^{c, d}	16.1	16.7	0.75	4.0	
Colombia	14.3	17.3	0.08	20.7	
Morocco	15.5	15.1	0.75	-3.1	
India	13.7	14.3	<0.01	4.3	
Venezuela	14.5	14.4	0.95	-0.9	
Peru	5.9	10.3	0.41	74.7	
Indonesia	10.9	8.9	0.32	-18.3	
West Africa^{c, e}	4.0	2.8	0.04	-30.1	

Notes: DDD=defined daily doses; No.=number.

a Statistical significance was determined using simple linear regression. Countries in bold declined $\geq 5\%$. **b** Sorted based on statin utilization in 2020, refer to **Error! Reference source not found.** **c** IQVIA does not provide country specific utilization for this region. **d** Central American countries included Costa Rica, El Salvador, Honduras, Guatemala, Nicaragua, and Panama. **e** West African countries included Benin, Burkina Faso, Cameroon, Chad, Democratic Republic of the Congo, Gabon, Guinea, Ivory Coast, Mali, Niger, Senegal, and Togo.